Abstract
This paper presents a realistic evaluation of the prevalence of type 2 diabetes mellitus (T2DM) among Polish schizophrenic patients who have sought treatment through the Polish National Health Fund in the years 2010-2017. Data from the National Health Fund database was used and T2DM and schizophrenia groups were defined according to International Classification of Diseases (ICD-10) codes. Demographic data were collected from the web page of Statistics Poland (GUS). The annual prevalence of T2DM and schizophrenia was estimated, and the age groups were categorised into eight sets. The incidence of schizophrenia in T2DM patients in the years 2010-2017 was measured, including relative risk and 95% confidence interval (95% CI). The incidence of T2DM has been assessed in various subtypes of schizophrenia. In the eight years of follow-up study, 1,481,642 patients with schizophrenia were included, of which 185,205 were also diagnosed with T2DM. This accounted for 12.50% of all patients with schizophrenia. The trend of comorbid schizophrenia (F20) and T2DM (E11) in the general population of patients with schizophrenia, who sought treatment through the National Health Fund, was relatively stable in the years 2010-2017. The relative risk of T2DM in those with schizophrenia was 8.33 (95% CI 8.23-8.43) in 2017. Taking actions to enable the detection of diabetes in patients with concomitant schizophrenia is well-grounded, although these actions should be gender-dependent. There is also a need to take adequate actions to improve the efficiency of diabetological care among patients with schizophrenia.
Highlights
Schizophrenia is a severe mental illness (SMI), characterised by cognitive, emotional, perceptual and behavioural disorders [1, 2]
Criteria for patient inclusion to the study were: 1) type 2 diabetes mellitus (T2DM) diagnosed according to the ICD-10 by a diabetologist [9]; 2) schizophrenia (F20) diagnosed by a psychiatrist according to ICD-10 [9]; and 3) patients benefiting from state medical care in the years 2010–2017
The conducted evaluation of the prevalence of schizophrenia and T2DM in the entire population of patients with schizophrenia indicates that the trend of coexistence of the two illnesses was relatively stable in the years 2010–2017 and remained around the level of 13%
Summary
Schizophrenia is a severe mental illness (SMI), characterised by cognitive, emotional, perceptual and behavioural disorders [1, 2]. It is believed that schizophrenia is a disease that has serious consequences for one’s health (disability, comorbidities, and complications), and economic and social
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
